相关实验视频
Updated: Jan 16, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
基于纳米粒子的抗癌药物的肝毒性:对毒性和缓解策略的洞察
Marcin Skorzynski1, Magdalena Krol2, Agata Braniewska1
1Department of Immunology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
纳米粒子抗癌药物面临肝脏毒性挑战. 像PEGylation和尺寸操纵这样的策略旨在减少肝细胞中纳米颗粒的积累,最大限度地减少损伤.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 毒理学 毒理学 毒理学
背景情况:
- 基于纳米粒子的抗癌药物显示出有前途,但导致严重的肝毒性.
- 肝脏的排毒作用使其易受库普费尔细胞和肝脏侧状内皮细胞的纳米粒子积累的影响.
- 这种积累会触发炎症反应 (ROS,IL-1β,TNF-α),导致肝细胞受损.
研究的目的:
- 审查当前的纳米颗粒药物输送系统.
- 探索减轻纳米粒子诱导肝毒性的策略.
- 讨论更安全的纳米粒子治疗方法的潜在修改.
主要方法:
- 关于纳米粒子修饰的现有文献的审查.
- 分析减少肝脏吸收和积累的策略.
- 讨论尺寸,电荷和表面修饰技术.
主要成果:
- 脂质体和石墨烯纳米颗粒的PEGylation通过网状内皮系统减少了肝脏的吸收.
- 诸如消极脂质结合,电荷操纵和尺寸控制等策略显示出潜在的.
- 对各种纳米粒子类型的pH响应药物释放机制正在开发中.
结论:
- 尽量减少纳米粒子在肝脏中的积累对于开发更安全的抗癌疗法至关重要.
- 表面修改和有针对性的输送是降低肝毒性的关键.
- 对纳米粒子设计的进一步研究可以提高治疗疗效,同时提高安全性.
更多相关视频
07:59A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...